Medication safety matters that need to be paid attention to when using Tepotinib (Tuodekang)

1. Overview of Tepotinib

Tepotinib (Tepotinib) is an oral small molecule METtyrosine kinase inhibitor, mainly used to treat METexon14skipping mutation (METex14)-positive advanced non-small cell lung cancer (NSCLC). Its mechanism of action is to specifically inhibit the MET signaling pathway and block the proliferation and migration of tumor cells, thereby achieving anti-tumor effects. As a targeted therapy drug, tepotinib has high efficacy and targeting properties, but drug safety still needs to be paid attention to during use to ensure the therapeutic effect and reduce risks.

2. Common adverse reactions and risk monitoring

Clinical studies have shown that a series of adverse reactions may occur during tepotinib treatment, including:

1. Edema: The most common is peripheral edema, which manifests as edema of the lower limbs or edema of the hands and feet. In severe cases, it may affect activities.

2.Gastrointestinal reactions: such as nausea, diarrhea, loss of appetite and mild vomiting.

3.Abnormal liver function: Some patients may experience elevated levels of ALT, AST or jaundice.

4.Hematological abnormalities: A few patients develop anemia, leukopenia, etc.

5.Pulmonary symptoms: Includes rare risk of interstitial lung disease (ILD) or pneumonia.

Therefore, regular blood routine, liver function, renal function and imaging examinations need to be performed during the use of tepotinib to detect abnormalities in time and take intervention measures.

3. Medication Safety Precautions

1. Take medication strictly according to doctor’s instructions

The recommended dose of tepotinib is usually once daily orally at a fixed dose. Patients should follow the doctor's instructions and should not increase or decrease the dosage or change the frequency of medication on their own. If you miss a dose, you should decide whether to take it again or skip it under the guidance of your doctor.

2.Monitor blood and liver function indicators

Blood routine, liver function and kidney function should be monitored regularly before and during treatment. If ALT, AST or bilirubin is found to be significantly elevated, the severity needs to be evaluated and temporary discontinuation of the drug, dose reduction, or adjuvant hepatoprotective treatment should be considered. Hematological abnormalities such as anemia or leukopenia should also be treated promptly and controlled through supportive treatment or dose adjustment if necessary.

3.Pay attention to edema and cardiovascular conditions

Tepotinib often causes lower extremity edema and weight gain. Mild edema can be relieved by raising the lower limbs, controlling salt intake, and exercising moderately. If edema seriously affects daily life, you should seek medical treatment promptly and evaluate whether you need to reduce the dose or temporarily stop the medication. Patients with a history of hypertension or heart failure need to pay more attention to cardiovascular indicators, regularly measure blood pressure and evaluate cardiac function.

4.Pay attention to lung symptoms and respiratory discomfort

Although the incidence of interstitial lung disease is low, you should be highly vigilant if you develop symptoms such as cough, difficulty breathing, or fever. Once patients develop relevant symptoms, they should seek medical treatment immediately. If necessary, suspend medication and undergo imaging examinations and anti-inflammatory treatments.

5.Drug interactions and dietary precautions

Tepotinib is mainly metabolized by CYP3A. Simultaneous use with potent CYP3A inhibitors or inducers may lead to abnormal blood concentration, affect efficacy or increase the risk of side effects. Patients should inform their doctors about all prescription, over-the-counter, and supplements they are taking. There is generally no need for strict dietary restrictions, but you should avoid taking Chinese medicines or supplements that may affect drug metabolism at the same time, unless your doctor agrees.

4. Patient self-management and follow-up recommendations

1.Establish daily monitoring habits

It is recommended that patients record daily weight, edema, blood pressure and symptom changes, and bring the records for regular follow-up visits to help doctors evaluate the efficacy and side effects.

2.Seek medical attention promptly if you feel unwell

During the course of taking the medicine, if severe gastrointestinal reactions, abnormal liver function, obvious edema or difficulty breathing occur, you should contact your doctor immediately to avoid delays in treatment.

3.Follow the follow-up plan

Doctors usually arrange laboratory tests and imaging reviews every 4 to 8 weeks, and adjust the dosage or treatment plan based on efficacy and tolerance. Strictly adhering to the follow-up plan can ensure drug efficacy and medication safety to the greatest extent.

4.Education and family support

Patients and their families should understand the possible adverse reactions of drugs and their treatment methods to improve medication compliance. At the same time, we should pay attention to mental health, maintain good living habits, and assist drug treatment to achieve the best effect.

Overall, tepotinib, as a targeted therapy, has significant efficacy, but safety still needs to be paid attention to. Through standardized medication use, regular monitoring, timely treatment of adverse reactions, and good self-management, most patients can obtain long-term clinical benefits while ensuring safety.

Reference link:https://www.drugs.com